Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis.
暂无分享,去创建一个
Adolf Pfefferbaum | Elfar Adalsteinsson | Scott W Atlas | Edith V Sullivan | Archana Rao | A. Pfefferbaum | E. Adalsteinsson | S. Atlas | E. Sullivan | A. Langer-Gould | R. Homer | Annette Langer-Gould | Ronald J Homer | Christiane Abbehusen Lima | A. Rao | C. A. Lima
[1] K. Lim,et al. Segmentation of MR Brain Images into Cerebrospinal Fluid Spaces, White and Gray Matter , 1989, Journal of computer assisted tomography.
[2] R I Grossman,et al. Total brain N-acetylaspartate , 2000, Neurology.
[3] W R Kinkel,et al. High‐Resolution Fluorodeoxyglucose Positron Emission Tomography Shows Both Global and Regional Cerebral Hypometabolism in Multiple Sclerosis , 1998, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[4] P. Matthews,et al. Thalamic neurodegeneration in multiple sclerosis , 2002, Annals of neurology.
[5] J Star-Lack,et al. Reduced spatial side lobes in chemical‐shift imaging , 1999, Magnetic resonance in medicine.
[6] N. Otsu. A threshold selection method from gray level histograms , 1979 .
[7] M S Buchsbaum,et al. Whole-brain diffusion MR histograms differ between MS subtypes , 2000, Neurology.
[8] P M Matthews,et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.
[9] K O Lim,et al. In vivo spectroscopic quantification of the N‐acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: Effects of normal aging , 1999, Magnetic resonance in medicine.
[10] E. Sullivan,et al. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease , 2000, The Lancet.
[11] G. Barker,et al. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis , 1997, Journal of neurology, neurosurgery, and psychiatry.
[12] P Kapeller,et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. , 2002, Brain : a journal of neurology.
[13] F. Mcdowell,et al. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.
[14] G. Glover,et al. Regularized higher‐order in vivo shimming , 2002, Magnetic resonance in medicine.
[15] G. Fein,et al. Biochemical alterations in multiple sclerosis lesions and normal‐appearing white matter detected by in vivo 31P and 1H spectroscopic imaging , 1994, Annals of neurology.
[16] P. Dupont,et al. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis , 1997, Multiple sclerosis.
[17] Kishore Bhakoo,et al. Spectral profiles of cultured neuronal and glial cells derived from HRMAS 1H NMR spectroscopy , 2002, NMR in biomedicine.
[18] H. Tallan. Studies on the distribution of N-acetyl-L-aspartic acid in brain. , 1957, The Journal of biological chemistry.
[19] M Rovaris,et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. , 2003, Brain : a journal of neurology.
[20] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[21] M W Weiner,et al. 1H MRSI of normal appearing white matter in multiple sclerosis , 1997, Multiple sclerosis.
[22] R. Lenkinski,et al. MR spectroscopy in the evaluation of enhancing lesions in the brain in multiple sclerosis. , 1996, AJNR. American journal of neuroradiology.
[23] K O Lim,et al. In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. , 1999, Archives of general psychiatry.
[24] J. Babb,et al. Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations. , 2002, Radiology.
[25] Hristian,et al. RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS , 2000 .
[26] O. Petroff,et al. Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, and GABA content of the epileptic human brain. , 1995, Magnetic resonance imaging.
[27] W. Mcdonald. Relapse, remission, and progression in multiple sclerosis. , 2000, The New England journal of medicine.
[28] C. Svarer,et al. Rate Dependence of Regional Cerebral Activation during Performance of a Repetitive Motor Task: A PET Study , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[29] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[30] R. Tarducci,et al. Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis. , 2002, Journal of neurology.
[31] David H. Miller,et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis , 2002, Annals of neurology.
[32] J. Frahm,et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. , 1999, AJNR. American journal of neuroradiology.
[33] Jullie W Pan,et al. Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T , 1996, Magnetic resonance in medicine.
[34] P. Matthews,et al. Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions , 1997, Annals of neurology.